Faculty of Medicine and Biomedical Sciences, University of Queensland, Brisbane, Queensland, Australia.
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Ann Surg. 2019 Apr;269(4):596-602. doi: 10.1097/SLA.0000000000003021.
The aim of the study was to determine the efficacy of laparoscopic rectal resection (Lap) versus open laparotomy and rectal resection (Open) for rectal cancer on locoregional recurrence (LRR) and disease-free survival (DFS) at 2 years.
Although a Lap approach to colon cancer surgery may offer similar oncological outcomes to Open with potentially less morbidity, this remains to be clearly established for the treatment of rectal cancer.
A randomized, multicenter noninferiority phase 3 trial of 475 patients with T1 to T3 rectal adenocarcinoma <15 cm from anal verge, given Lap or Open and followed for a minimum 2 years to assess LRR, DFS, and overall survival (OS).
Secondary endpoint analyses included 450 patients (95%) without metastases at baseline (mean age 64; 34% women) who received Lap (n = 225) or Open (n = 225). Median follow-up was 3.2 years (range: 0.1-5.4 yrs). LRR cumulative incidence at 2 years: Lap 5.4%; Open 3.1% [difference, 2.3%; 95% confidence interval (CI), -1.5% to 6.1%; hazard ratio (HR) 1.7; 95% CI, 0.74-3.9]. DFS at 2 years: Lap 80%; Open 82% (difference, 2.0%; 95% CI, -9.3% to 5.4%; HR for recurrence or death, 1.17; 95% CI, 0.81-1.68; P = 0.41). After adjustment for baseline factors HR = 1.07 (95% CI, 0.7-1.6). OS at 2 years: Lap 94%; Open 93% (difference 0.9%; 95% CI, -3.6% to 5.4%).
Laparoscopic surgery for rectal cancer did not differ significantly from open surgery in effects on 2-year recurrence or DFS and OS. Confidence intervals included potentially clinically important differences favoring open resection, so that the combination of primary and secondary study endpoints may not support laparoscopic resection of rectal cancer as a routine standard of care and further follow-up is required.
本研究旨在确定腹腔镜直肠切除术(Lap)与开腹直肠切除术(Open)治疗直肠腺癌的局部复发(LRR)和无病生存(DFS)的疗效,以 2 年为时间点。
虽然腹腔镜结直肠癌手术可能提供与开腹手术相似的肿瘤学结果,且潜在的发病率更低,但这对于直肠肿瘤的治疗仍有待明确。
一项随机、多中心的非劣效性 III 期临床试验,共纳入 475 例距肛门 15cm 以内的 T1-T3 直肠腺癌患者,分别接受 Lap 或 Open 治疗,并随访至少 2 年,以评估 LRR、DFS 和总生存(OS)。
次要终点分析纳入 450 例基线无转移的患者(平均年龄 64 岁,34%为女性),其中 225 例接受 Lap,225 例接受 Open。中位随访时间为 3.2 年(范围:0.1-5.4 年)。2 年时 LRR 的累积发生率:Lap 组为 5.4%,Open 组为 3.1%[差异为 2.3%;95%置信区间(CI)为-1.5%至 6.1%;风险比(HR)为 1.7;95%CI 为 0.74-3.9]。2 年时 DFS:Lap 组为 80%,Open 组为 82%(差异为 2.0%;95%CI 为-9.3%至 5.4%;复发或死亡的 HR 为 1.17;95%CI 为 0.81-1.68;P = 0.41)。调整基线因素后 HR = 1.07(95%CI 为 0.7-1.6)。2 年时 OS:Lap 组为 94%,Open 组为 93%(差异为 0.9%;95%CI 为-3.6%至 5.4%)。
与开腹手术相比,腹腔镜直肠肿瘤切除术在 2 年时的复发或 DFS 和 OS 方面无显著差异。置信区间包含了有利于开腹切除的潜在临床重要差异,因此主要和次要研究终点的组合可能不支持腹腔镜直肠肿瘤切除术作为常规治疗标准,需要进一步随访。